Torrent Pharma Recalls Losartan Potassium Tablets Due to Impurity
Torrent Pharma Inc. is recalling Losartan Potassium Tablets, 100 mg, because FDA testing found an impurity above acceptable levels.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, and the presence of a nitrosamine impurity (NMBA) above acceptable levels constitutes a significant health risk, aligning with the 'Severe' criteria for significant injury reports or high-risk contamination.
Plain-English summary
Torrent Pharma Inc. is recalling Losartan Potassium Tablets, USP, 100 mg, in 90-count and 1000-count bottles. The recall involves 121,668 bottles distributed nationwide in the United States and Puerto Rico.
The recall was initiated because FDA laboratory testing confirmed the presence of an impurity, N-Methylnitrosobutyric acid (NMBA), in the finished product above the interim acceptable daily intake level. This finding represents a Current Good Manufacturing Practice (CGMP) deviation.
Consumers who have these specific products should stop using them and contact their healthcare provider or pharmacist for guidance on alternative treatment options. The affected lots and expiration dates are: 90-count bottles with Lots 4DU3E014 and 4DU3E015 (exp 1/31/2021), Lot 4DU3E065 (exp 7/31/2021); and 1000-count bottles with Lot 4DU3D018 (exp 11/30/2020), and Lots 4DU3E062 and 4DU3E063 (exp 6/30/2021).
The recalled product
- Product
- LOSARTAN POTASSIUM TABLETS, USP, 100 mg, a) 90-count (NDC: 13668-115-90), b) 1000-count (NDC: 13668-115-10), per bottle, Rx only, Manufactured by: Torrent Pharmaceuticals LTD, Indrad-382 721, Dist. Mehsana India. For: Torrent Pharma, Inc, 150 Allen Road, Suite 102, Basking Ridg
- Manufacturer
- Torrent Pharma Inc.
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 121,668
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (12)
- Count
- lots
- expiry: [90-count bottle] Lots 4DU3E014
- 4DU3E015
- exp 1/31/2021
- Lot 4DU3E065
- exp 7/31/2021
- [1000-count bottle] Lot 4DU3D018
- exp 11/30/2020
- Lots 4DU3E062
- 4DU3E063
- exp 6/30/2021
Distribution
Part of a larger recall action
This product is one of 6 recalled by Torrent Pharma Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 6 products in this recall →Related recalls
Same manufacturer · Torrent Pharma Inc.
See all →- HighFluoxetine Tablets USP 20 mg Recalled for N-Nitroso Contamination
FDA (Drugs) · 2025-06-11
- SevereFluoxetine Tablets 20 mg Recalled for N-Nitroso Impurity
FDA (Drugs) · 2025-06-11
- High
- ModerateCarbamazepine tablets recalled for failed dissolution specifications
FDA (Drugs) · 2022-01-19
- ModerateTelmisartan and Hydrochlorothiazide Tablets Recalled for Superpotency
FDA (Drugs) · 2021-12-22
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17